Therapeutic doses of ATRA can stop the PML-RARα-mediated repression of target genes and release the differentiation block in promyelocytes (58), sometimes catalyzing a dynamic process clinically apparent as APL differentiation syndrome. This evidence concerns the gene RARA and acute promyelocytic leukemia.